Methods and compositions for wound treatment

Patent metadata

Field	Value
Publication number	US-9387253-B2
Application number	US-201514934425-A
Country	US
Kind code	B2
Filing date	Nov 6, 2015
Priority date	Dec 21, 2010
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

First claim

What is claimed is:

1. A composition for treatment of a wound in a subject comprising:
a carrier,
a hemostatic agent and
a wound targeting moiety comprising an antibody specific for actin, wherein the carrier contains the hemostatic agent and is conjugated to the antibody and, further wherein the wound targeting moiety facilitates local delivery of the hemostatic agent to wounded tissue by binding to an actin protein exposed upon wounding of the subject.

2. The composition of claim 1 , wherein the hemostatic agent is a self-assembling peptide.

3. The composition of claim 2 , wherein the self-assembling peptide creates a hydrogel.

4. The composition of claim 3 , wherein the self-assembling peptide is AMAX3-WW.

5. The composition of claim 1 , wherein the carrier is a liposome.

6. A composition for treatment of a wound in a subject comprising:
a carrier,
a hemostatic agent, and
a wound targeting moiety comprising an antibody specific to a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope, wherein the carrier contains the hemostatic agent and is conjugated to the antibody, and wherein the antibody facilitates local delivery of the hemostatic agent to wound tissue by binding to an exposed cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope exposed upon wounding of the subject.

7. The composition of claim 6 , wherein the hemostatic agent is a self-assembling peptide.

8. The composition of claim 7 , wherein the self-assembling peptide creates a hydrogel.

9. The composition of claim 8 , wherein the self-assembling peptide is AMAX3-WW.

10. The composition of claim 6 , wherein the carrier is a liposome.

11. A composition for treatment of a wound in a subject comprising:
a carrier,
an anticoagulant and
a wound targeting moiety comprising an antibody specific for actin, wherein the carrier contains the anticoagulant and is conjugated to the antibody and, further wherein the wound targeting moiety facilitates local delivery of the anticoagulant agent to wounded tissue by binding to an actin protein exposed upon wounding of the subject.

12. The composition of claim 11 , wherein the anticoagulant is an anti-platelet agent.

Assignees

• Leidos Inc

Inventors

• Dresios John
• Griffey Richard

Classifications

• A61K38/1777

  Integrin superfamily · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• A61K39/44

  Antibodies bound to carriers · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• A61K47/6801

  Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent · CPC title